USD10
ABOS Shares
About Acumen PharmaceuticalsAcumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
USD10
ABOS Shares
About Acumen PharmaceuticalsAcumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$194.97M
OPEN PRICE
$2.49
LOW (1Y)
$0.8551
HIGH (1Y)
$3.60
LOW (24H)
$2.49
HIGH (24H)
$2.75
VOLUME (24H)
$636.08K
17.16%
Price history
Time | Price | Change |
|---|---|---|
Today | $2.49 | |
1 Day | $2.70 | 0.00% |
1 Week | $2.26 | |
1 Month | $3.31 | |
1 Year | $1.05 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
